Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

International Journal of Pharmaceutics

Volumn 344, Issue 1-2, 2007, Pages 9-15

  Garbayo, E ^a   Ansorena, E ^a   Lanciego, J L ^b   Aymerich, M S ^b   Blanco Prieto, M J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

GDNF; Parkinson's disease; Protein purification

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG PURIFICATION; GLYCOSYLATION; INFUSION PUMP; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PURIFICATION;

ANIMALS; CELL LINE; CELLS, CULTURED; CRICETINAE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLYCOSYLATION; NEURITES; RATS; RECOMBINANT PROTEINS;

EID: 34648834760     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.04.003     Document Type: Article

References (21)

1. Barroso-Chinea P., Cruz-Muros I., Aymerich M.S., Rodriguez-Diaz M., Afonso-Oramas D., Lanciego J.L., and Gonzalez-Hernandez T. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur. J. Neurosci. 21 (2005) 1815-1827
2. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., and Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann. Neurol. 58 (2005) 224-233
3. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 21 (1996) 252-255
4. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
5. Hou J.G., Lin L.F., and Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66 (1996) 74-82
6. Hutchinson, M., Gurney, S., Newson, R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J. Neurosci. Methods, in press.
7. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
8. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 21 (1993) 1130-1132
9. Lin L.F., Zhang T.J., Collins F., and Armes L.G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63 (1994) 758-768
10. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., and Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 11 (2005) 703-704
11. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7 (1992) 117-124
12. Powers J.F., Schelling K., Brachold J.M., Tsokas P., Schayek H., Friedman E., and Tischler A.S. High-level expression of receptor tyrosine kinase Ret and responsiveness to Ret-activating ligands in pheochromocytoma cell lines from neurofibromatosis knockout mice. Mol. Cell. Neurosci. 20 (2002) 382-389
13. Rodriguez-Oroz M.C., Zamarbide I., Guridi J., Palmero M.R., and Obeso J.A. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1382-1385
14. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., and Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11 (1999) 1554-1566
15. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
16. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., Walton A., Wagner R., and Young A.B. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg. Focus. 15 (2006) E1
17. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 26 (1995) 335-339
18. Trombetta E.S. The contribution of N-glycans and their processing in the endoplasmic reticulum to glycoprotein biosynthesis. Glycobiology 13 (2003) 77R-91R
19. Trupp M., Ryden M., Jornvall H., Funakoshi H., Timmusk T., Arenas E., and Ibanez C.F. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J. Cell. Biol. 130 (1995) 137-148
20. Walsh G., and Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24 (2006) 1241-1252
21. Wang C.Y., Ni J., Jiang H., Hsu T.A., Dugich-Djordjevic M., Feng L., Zhang M., Mei L., Gentz R., and Lu B. Cloning and characterization of glial cell line-derived neurotrophic factor receptor-B: a novel receptor for members of glial cell line-derived neurotrophic factor family of neurotrophic factors. Neuroscience 83 (1998) 7-14